Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Using Cryoballoon Ablation as Initial Treatment for Persistent Atrial Fibrillation

NCT: NCT04942834 · COMPLETED

NCT IDNCT04942834
StatusCOMPLETED
Start Date2021-10-01
Completion2025-08-23
SponsorRuijin Hospital (OTHER)
First posted
Last updated

Brief Summary

This study is to assess the effectiveness and safety of using cryoballoon ablation comparing with anti-arrhythmic drug therapy as initial treatment for naive patients with persistent atrial fibrillation.

Frequently Asked Questions

What is Using Cryoballoon Ablation as Initial Treatment for Persistent Atrial Fibrillation?

Using Cryoballoon Ablation as Initial Treatment for Persistent Atrial Fibrillation is a clinical trial registered under NCT04942834. Current status: COMPLETED.

What is the status of NCT04942834?

The current status of NCT04942834 (Using Cryoballoon Ablation as Initial Treatment for Persistent Atrial Fibrillation) is: COMPLETED.

When did Using Cryoballoon Ablation as Initial Treatment for Persistent Atrial Fibrillation start?

Using Cryoballoon Ablation as Initial Treatment for Persistent Atrial Fibrillation started on 2021-10-01.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑